The Blue Jet Healthcare QIP, one of the notable capital markets transactions of July 2026, saw three top-tier law firms step in across issuer and placement agent mandates. Blue Jet Healthcare Limited raised ₹800 crore through a Qualified Institutions Placement of equity shares, with AZB & Partners, Cyril Amarchand Mangaldas, and Hogan Lovells each taking distinct advisory roles. The transaction closed on July 9, 2026, drawing strong institutional participation from marquee investors.
Introduction
Blue Jet Healthcare Limited is a specialty pharmaceutical and healthcare ingredients company operating as an end-to-end Contract Development and Manufacturing Organization (CDMO). The company’s core focus areas include contrast media intermediates, high-intensity sweeteners, and niche active pharmaceutical ingredients (APIs). Notably, Blue Jet Healthcare is India’s first manufacturer of saccharin.
The transaction involved a Qualified Institutions Placement (QIP) of 1,58,10,276 equity shares to qualified institutional buyers. The QIP was undertaken to ensure compliance with the minimum public shareholding requirements prescribed under the Securities Contracts (Regulation) Rules, 1957. Placement agents for the transaction were Motilal Oswal Investment Advisor Limited and ICICI Securities Limited.
Deal Value
Blue Jet Healthcare Limited raised an aggregate of ₹800 crore (₹8,000 million) through this QIP. The equity shares were allotted at an issue price of ₹506 per share, representing a discount of ₹25.70, or 4.83%, to the floor price of ₹531.70 per share, in accordance with applicable SEBI guidelines. The QIP window opened on July 6, 2026 and the allotment was approved by the company’s Investment and Finance Committee on July 9, 2026.
Legal Teams Involved
AZB & Partners — Counsel to Blue Jet Healthcare (Issuer)
AZB & Partners advised Blue Jet Healthcare Limited on this QIP. Further details of the advising team were not disclosed.
Cyril Amarchand Mangaldas — Counsel to the Placement Agents
Cyril Amarchand Mangaldas advised the placement agents, Motilal Oswal Investment Advisor Limited and ICICI Securities Limited, on this QIP.
The transaction team comprised:
- Ravi Dubey — Partner, Regional Co-Head – Capital Markets – West
- Oishika Dasgupta — Partner
- Abishek Sankar — Senior Associate
- Akshita Dhawan — Associate
- Nikshetaa Jain — Associate
- Chinmay Jumde — Associate
- Mitali Mangalam — Associate
Hogan Lovells — International Legal Counsel to the Placement Agents
Hogan Lovells served as the international legal counsel for the placement agents on this transaction.
The transaction team comprised:
- Biswajit Chatterjee — Head of the India Practice and Dubai Office Managing Partner
Significance and Impact
This QIP carries regulatory significance beyond the fundraise itself: it was structured specifically to bring Blue Jet Healthcare into compliance with the minimum public shareholding norms under the Securities Contracts (Regulation) Rules, 1957. The offering was oversubscribed by leading institutional investors, with a systemically important NBFC and multiple schemes of a prominent domestic mutual fund together accounting for the substantial majority of the allotment.
The transaction also reflects the continuing strength of the India capital markets across the specialty pharmaceuticals and CDMO space. Blue Jet Healthcare’s positioning as India’s first saccharin manufacturer and its end-to-end CDMO capabilities across contrast media intermediates and niche APIs adds strategic depth to what institutional buyers were backing.
The involvement of both domestic powerhouses — AZB & Partners and Cyril Amarchand Mangaldas — alongside the global reach of Hogan Lovells on the same QIP underscores the cross-border institutional character of the placement. For deal-tracking purposes, see the Deal Meter for a running record of law firm activity across Indian capital markets transactions.
The Blue Jet Healthcare ₹800 crore QIP, successfully closed on July 9, 2026, represents a significant equity capital markets event in the specialty pharma and CDMO sector. With three leading firms — AZB & Partners, Cyril Amarchand Mangaldas, and Hogan Lovells — each advising distinct principals, the transaction exemplifies the multi-counsel structure now standard in large Indian QIPs. The deal strengthens Blue Jet Healthcare’s public float while meeting its regulatory shareholding obligations.
Disclaimer: This article is for informational purposes only and does not constitute legal advice. It is based on the details provided and publicly available sources.
